Ligand Pharmaceuticals

Update in progress

LGND (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that develops and licenses pharmaceutical assets worldwide. Its portfolio spans infectious disease, cancer, immunology, neurology, cardiology, ophthalmology, respiratory and rare diseases, including products such as Pradefovir, Posaconazole, Voriconazole, EVOMELA, KYPROLIS, FILSPARI, VAXNEUVANCE, VEKLURY, and others. Founded in 1987, it is based in Jupiter, Florida.

Company score

Sentiment: 0.22; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.11; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.03; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.04; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.13; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive